VEGF as an inhibitor of tumor vessel maturation: Implications for cancer therapy

Expert Opinion on Biological Therapy

Volumn 9, Issue 11, 2009, Pages 1347-1356

  Greenberg, Joshua I ^a,b   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mural cells; Normalization; PDGF; Pericytes; Tumor angiogenesis; VEGF

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CARBOPLATIN; CT 322; FLUOROURACIL; FOLINIC ACID; IMC 1121B; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; BLOOD VESSEL REACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; RECTUM CANCER; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 70350655979     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903208883     Document Type: Review

References (71)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-1186
2. Auerbach R, Kubai L, Knighton D, et al. A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 1974;41:391-394
3. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:442-447
4. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic molecule. Science 1989;246:1306-1309 (Pubitemid 20066716)
5. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985
6. Heldin CH, Wasteson A, Westermark B. Partial purification and characterization of platelet factors stimulating the multiplication of normal human glial cells. Exp Cell Res 1977;109(2):429-437 (Pubitemid 8222981)
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor in induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844 (Pubitemid 23132159)
8. Fukumura D, Xavier R, Sugiura T. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94(6):715-725 (Pubitemid 28436004)
9. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-13340
10. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266(18):11947-11954 (Pubitemid 21907041)
11. Millauer B, Wizigmann-Voos S, Schnurch H. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846 (Pubitemid 23110226)
12. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272(51):32521-32527 (Pubitemid 28011938)
13. Dougher-Vermazen M, Hulmes JD, Böhlen P, et al. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF receptor. Biochem Biophys Res Commun 1994;205:728-738 (Pubitemid 124009490)
14. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-924 (Pubitemid 30054898)
15. Jiang BH, Zheng JZ, Aoki M, et al. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000;97:1749-1753 (Pubitemid 30118514)
16. Henkemeyer M, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995;377:695-701
17. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1- d e ficient mice. Nature 1995;376:62-66
18. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70
19. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-943 (Pubitemid 36889938)
20. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002;109(3):327-336 (Pubitemid 34141806)
21. D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007;171(1):1
22. Grosskreutz CL, Anand-Apte B, Dupláa C, et al. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 1999;58(2):128-136 (Pubitemid 29419938)
23. Couper LL, Bryant SR, Eldrup-Jorgenson J, et al. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ Res 1997;81:932-939
24. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15(4):197-204 (Pubitemid 38781045)
25. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004;15(4):205-213
26. Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439 (Pubitemid 38340290)
27. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-1316 (Pubitemid 29473317)
28. Hwang RF, Yokoi K, Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003;9(17):6534-6544 (Pubitemid 38031842)
29. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003111(9):1287-1295
30. Sennino B, Falcón BL, McCauley D, et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67(15):7358-7367 (Pubitemid 47206566)
31. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003;264:275-288
32. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001;15:1239-1241
33. Shih SC, Ju M, Liu N, et al. Transforming growth factor β1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci 2003;100:15859-15864 (Pubitemid 38021080)
34. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006;312:623-629
35. Deryugina EI, Quigley JP. Methods in enzymology angiogenesis: in vivo systems, Part A. Volume 444, 2008, Chapter 2 Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Elsevier; 2008. p. 21-41
36. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-924 (Pubitemid 30054898)
37. Alavi AS, Acevedo L, Min W, et al. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 2007;6:2766-2772 (Pubitemid 46548965)
38. Chen RR, Silva EA, Yuen WW, et al. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007;24(2):258-264
39. Levanon K, Varda-Bloom N, Greenberger S, et al. Vascular wall maturation and prolonged angiogenic effect by endothelial-specific platelet-derived growth factor expression. Pathobiology 2006;73(3):149-158 (Pubitemid 44699473)
40. Pietras K, Pahler J, Bergers G, et al. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5(1):e19
41. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9(5):604-613 (Pubitemid 36597108)
42. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118(Pt 16):3759-3768 (Pubitemid 41309422)
43. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456(7223):809-813
44. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161(6):1163-1177 (Pubitemid 36870177)
45. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 1990;345A:317-330
46. Abramsson A, Berlin O, Papayan H. Paulin, M. Shani, and C. Betsholtz. Analysis of mural cell recruitment to tumor vessels. Circulation 2002;105(1):112-117 (Pubitemid 34049151)
47. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40 (Pubitemid 43108832)
48. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
49. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature 2004;427(6976):695
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 (Pubitemid 38702844)
51. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
52. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-1096
53. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666- 2676
54. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59(20):5209-5218 (Pubitemid 29503984)
55. Hampton T. "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. J Am Med Assoc 2004;292:419-420
56. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-4560 (Pubitemid 32103640)
57. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-147 (Pubitemid 38524883)
58. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456(7223):814-818
59. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):15-24 (Pubitemid 30217701)
60. Benjamin LE, Golijanin D, Itin A. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-165 (Pubitemid 29053133)
61. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-563 (Pubitemid 40017699)
62. Dorafshar AH, Angle N, Bryer-Ash M, et al. Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation. J Surg Res 2003;114(2):179-186 (Pubitemid 37237683)
63. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-4015 (Pubitemid 30636574)
64. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369-3372
65. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167(2):223-229 (Pubitemid 39435066)
66. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008;8(4):309-316
67. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13(13):3942-3950
68. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-223
69. Ebos JML, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-239
70. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136(5):839-851
71. Jain RK, Duda DG,Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Clin Pract Oncol 2006;3(12):693-697